Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|November 6, 2015
Safeguards Pharmacies Can Put in Place to Avoid Issues with Controlled Substance Prescriptions
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some safeguards independent pharmacies can implement to avoid issues with controlled substance prescriptions.
Advertisement
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some safeguards independent pharmacies can implement to avoid issues with controlled substance prescriptions.
This video was recorded at the National Community Pharmacists Association's (NCPA) 2015 Annual Convention.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Harnessing the Gut Microbiome for Enhanced CAR T Cell Therapy
5